Quick Answer
UNITED THERAPEUTICS Corp reported Revenue (ASC 606) of $3.18 billion for fiscal year 2025.
UNITED THERAPEUTICS Corp Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $3.18B | +10.6% |
| 2024 | $2.88B | +23.6% |
| 2023 | $2.33B | +20.2% |
| 2022 | $1.94B | +14.9% |
| 2021 | $1.69B | +13.6% |
| 2020 | $1.48B | +2.4% |
| 2019 | $1.45B | -11.0% |
| 2018 | $1.63B | -5.7% |
| 2017 | $1.73B | +7.9% |
| 2016 | $1.60B | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $799.50M | +6.8% | +0.1% |
| June 30, 2025 | $798.60M | +11.7% | +0.5% |
| March 31, 2025 | $794.40M | +17.2% | +6.1% |
| September 30, 2024 | $748.90M | +22.9% | +4.8% |
| June 30, 2024 | $714.90M | +19.8% | +5.5% |
| March 31, 2024 | $677.70M | +33.7% | +11.2% |
| September 30, 2023 | $609.40M | +18.1% | +2.2% |
| June 30, 2023 | $596.50M | +27.8% | +17.7% |
- UNITED THERAPEUTICS Corp showed an increase of +10.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, UNITED THERAPEUTICS Corp’s revenue (asc 606) has grown by 99.1% (from $1.60 billion to $3.18 billion).
- The most recent figure is from UNITED THERAPEUTICS Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: